Anagrelide — ET 2L cytoreduction (HU-intolerant / HU-resistant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-ANAGRELIDE`

ID	`REG-ANAGRELIDE-ET`
Type	Regimen
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-MPN-2015` `SRC-NCCN-MPN-2025` `SRC-PT1-HARRISON-2005`

Notes

ET 2L cytoreduction for HU-intolerant or HU-resistant patients per PT-1 (Harrison 2005). PT-1 noted MORE arterial thrombosis + serious bleeding + MF progression on anagrelide vs HU — therefore anagrelide is NOT preferred 1L; reserved for HU failure. Pegylated interferon-α (e.g. ropeginterferon) is an alternative 2L (especially for younger patients with disease-modification goal). Cardiac baseline assessment recommended (ECG ± echo) before initiation if any cardiac comorbidity. STUB — requires Clinical Co-Lead signoff.

Used By

Indication

IND-ET-2L-ANAGRELIDE - IND-ET-2L-ANAGRELIDE
IND-PV-ANAGRELIDE-CONTINUOUS - IND-PV-ANAGRELIDE-CONTINUOUS